BDTX-4933 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This BDTX-4933 Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Phase 1/2
Highest phase
2
Registered trials
Result records
1
Matched deals
Executive recommendation: HOLD
Decision memo
The deal validates strategic interest, but the absence of a matched public result record in the MCP dataset leaves efficacy and therapeutic-index risk unresolved.
The central underwriting question is whether BDTX-4933 can convert its Small molecule drug profile and BRAF x RAS biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | BDTX-4933 (query alias: BDTX-4933) |
|---|---|
| Modality / target | Small molecule drug; BRAF x RAS; BRAF inhibitors, RAS inhibitors |
| Highest global status | Phase 1/2 |
| Originator | Black Diamond Therapeutics, Inc. |
| Active developers | Institut de Recherches Internationales Servier, Les Laboratoires Servier SAS, Servier (Beijing) Pharmaceutical R&D Co., Ltd. |
The MCP disease footprint includes Adenocarcinoma of large intestine, BRAF mutation Solid Tumors, Brain metastases. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT05786924 | Phase 1/2 | Recruiting | 554 | Dose Escalation: Incidence of dose-limiting toxicities (DLTs) |
| JPRN-jRCT2031250784 | Phase 1/2 | 募集中 | 30 | ・用量漸増：用量制限毒性（DLT）の発現率 ・用量漸増：有害事象（AE）、重篤な有害事象（SAE）の発生件数 ・用量最適化／用量拡大：客観的奏効（OR）率 |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Evidence gap
The Clinical Trials MCP returned no matched public result record. This is a gating diligence gap, not evidence of failure.
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
BDTX-4933 addresses Adenocarcinoma of large intestine, BRAF mutation Solid Tumors, Brain metastases. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2025-03-19 | Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy | Phase 1 | US$70.0M upfront; US$710.0M milestones |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
HOLD
The deal validates strategic interest, but the absence of a matched public result record in the MCP dataset leaves efficacy and therapeutic-index risk unresolved.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
